N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
N/A N=163 New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Alzheimer Disease · Behavioral Disorders · Cognitive Impairment
Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1
Phase 2 N=75 Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
Phase 2 N=46 Dapagliflozin In Alzheimer's Disease
Alzheimer Disease
Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio
Phase 2 N=22 Alzheimer's Disease Acitretin Medication
Alzheimer Disease
Primary: Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline — 1.251; 0.8741 fold change…
N/A N=430 Dementia Symptom Management at Home Program
Dementia
Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale
Phase 2 N=65 Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
Alzheimer's Disease · Healthy Non-elderly and Elderly Adults
Primary: Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. — 0; 0; 0; 0 Participants
Phase 4 N=110 Antipsychotic Discontinuation in Alzheimer's Disease
Alzheimer Disease · Psychotic Disorders · Agitation
Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02
Phase 3 N=208 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Dementia, Alzheimer Type
Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802
Phase 3 N=522 Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Agitation in Participants With Dementia of the Alzheimer's Type
Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789
Phase 1 N=106 A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
Alzheimer's Disease
Primary: Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4 — -0.10; -0.07 Score on a scale — p=0.231
Phase 2 N=128 Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236
Phase 3 N=366 Addressing Dementia Via Agitation-Centered Evaluation
Agitation in Patients With Dementia of the Alzheimer's Type · Alzheimer Disease · Agitation,Psychomotor
Primary: Change in CMAI Total Score — -15.4; -10.0; -11.5 score on a scale — p=0.010
N/A N=10 Musical Engagement of Brain LObes in Alzheimer's Disease Patients StudY
Alzheimer Disease · Dementia · Music Therapy
Primary: Changes in Intervention Response as Evaluated by the Clinical Global Impression of Change (CGIC) — 0; 0; 5; 2 Participants
Phase 3 N=387 Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Agitation in Patients With Dementia of the Alzheimer's Type
Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…
Phase 3 N=164 Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
Mild Cognitive Impairment · Prodromal Alzheimer's Disease
Primary: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline — 1.1; .9 score on a scale
N/A N=38 Age-related Hearing Loss and Lexical Disorders
Alzheimer Disease · Presbycusis · Lexical Syntactic Disorder
Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale
N/A N=10 Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
N/A N=548 Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
Alzheimer Disease · Mild Cognitive Impairment · Memory Disorders
Primary: Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC) — 0.94; 0.91 probability
Phase 2 N=77 Treatment of Psychosis and Agitation in Alzheimer's Disease
Alzheimer's Disease · Psychosis · Agitation
Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53
N/A N=884 Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Dementia · Dementia, Vascular · Dementia With Lewy Bodies
Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522
Phase 1 N=88 Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5; 3; 10; 8 Participants
Phase 2 N=80 Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline (Day 1) in Global and Regional Indices of Cerebral Metabolic Rate of Glucose (CMRglu) at Month 12 — -0.2793; -0.0887; -0.3143; -0.0786 Milligrams…
Phase 3 N=1,468 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives…
N/A N=20 SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
Mild Cognitive Impairment · Healthy Aging
Primary: Comprehension/Recall of Results - Personal Information Score - PARTICIPANT — 82.40; 94.60; 69.40; 90.80 percentage correct
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
Phase 3 N=579 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort — 1.6; -0.2; 0.6; 0.9…